MRK
Merck & Co., Inc.Healthcare · $367.3B market cap
Verdict
Share price
$144.30
close of Oct 3, 2026
Fair value
$72.78
Sticker Price
Payback Price
$29.11
buy price
MRK is Overpriced: at $144.30 it trades 98% above its fair value of $72.78. Its buy price (Payback Price) is $29.11, 80% below today's price. Business quality is limited: only 1 of 5 key numbers clears the 10% bar.
How we valued it
Dividend Discount Model. It has paid a dividend for 10+ years in a row, raised it most years, and yields over 2%. For a steady payer like this, the dividend is the best guide to value.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow MRK
Get notified when it reaches its buy price of $29.11. Free.
Create a free accountSuperinvestors
10 of the investors we track hold MRK. In Q2 2026, 1 added and 1 trimmed. Who we track
Bill Nygren
Oakmark Funds · as of Q2 2026
$1.6B
12,073,109 shares
Sarah Ketterer
Causeway Capital Management · as of Q2 2026
$122.7M
954,932 shares
Kahn Brothers Group
Kahn Brothers Group · as of Q2 2026
$27.3M
227,288 shares
Prem Watsa
Fairfax Financial Holdings · as of Q2 2026
$22.2M
172,900 shares
Dodge & Cox Funds
Dodge & Cox Funds · as of Q2 2026
$17.4M
135,750 shares
Show all 10 holdersShow fewer
Mairs & Power Funds
Mairs & Power Funds · as of Q2 2026
$6.6M
51,519 shares
Christopher Bloomstran
Semper Augustus · as of Q2 2026
$5.7M
44,633 shares
Richard Pzena
Pzena Investment Management · as of Q2 2026
$323K
2,511 shares
David Katz
Matrix Asset Advisors · as of Q2 2026
$215K
1,671 shares
Thomas Russo
Gardner Russo & Quinn · as of Q2 2026
$211K
1,642 shares
Insider activity
Since Jun 30, 2026: no open-market purchases, 13 sales worth $25.6M and 11 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Guindo Chirfi
EVP, Access, Policy & Comms · 2026-08-13
Sold
$1.4M
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth · 2026-08-12
Sold
$79K
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth · 2026-08-12
Sold
$1.5M
Zachary Jennifer
EVP, General Counsel · 2026-08-12
Sold
$10.7M
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth · 2026-08-11
Sold
$718K
Show all 13 salesShow fewer
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth · 2026-08-11
Sold
$973K
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth · 2026-08-10
Sold
$2.7M
Guindo Chirfi
EVP, Access, Policy & Comms · 2026-08-06
Sold
$2.0M
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth · 2026-08-06
Sold
$39K
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth · 2026-08-06
Sold
$644K
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth · 2026-08-06
Sold
$105K
Williams David Michael
EVP,Chief Info&Digital Officer · 2026-08-05
Sold
$4.5M
Maraldo David R.
EVP & Pres. MMD · 2026-08-05
Sold
$346K
Other filings
Zachary Jennifer
EVP, General Counsel · 2026-08-12
Option exercise
$4.9M
Zachary Jennifer
EVP, General Counsel · 2026-08-12
Option exercise
$1.1M
Williams David Michael
EVP,Chief Info&Digital Officer · 2026-08-05
Option exercise
$357K
Williams David Michael
EVP,Chief Info&Digital Officer · 2026-08-05
Option exercise
$1.0M
Williams David Michael
EVP,Chief Info&Digital Officer · 2026-08-05
Option exercise
$2.6M
Show all 11 other filingsShow fewer
Maraldo David R.
EVP & Pres. MMD · 2026-08-05
Option exercise
$228K
Maraldo David R.
EVP & Pres. MMD · 2026-08-05
Option exercise
$465K
Maraldo David R.
EVP & Pres. MMD · 2026-08-05
Option exercise
$846K
Coe Mary Ellen
director · 2026-06-30
Award
233.463 shares
Karsanbhai Surendralal Lanca
director · 2026-06-30
Award
126.459 shares
Seidman Christine E
director · 2026-06-30
Award
63.23 shares
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops…
Drug Manufacturers - General
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works